Double Pet Project : A Comparison Between 11C-Acetate and 11C-acetoacetate Heart and Kidney Uptake

• Sponsor: Université de Sherbrooke (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05238805
• Collaborator: Nestlé Health Science Spain (Industry)
• Enrollment: 10
• Arm: 1
• Anticipated Duration (Months): 10

Study Details

Study Description

Brief Summary

The objective of this study is to make a comparison between 11C-acetate and 11C-Acetoacetate heart and kidney metabolism

Condition or Disease	Intervention/Treatment	Phase
Ketoses, Metabolic	Radiation: Observational heart and kidney on siemens TEP scan	N/A

Detailed Description

Healthy people will have two positron emission tomography scan to perform. One, with a 11C-Acetate Tracer and the other with 11C-Acetoacetate. The results will allow to determine if both tracers are used in a similar way but the organs and see if the investigators can use the already validated analyse method for acetate to make acetoacetate analysis

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 10 participants
• Allocation: N/A
• Intervention Model: Sequential Assignment
• Intervention Model Description: Participants will have to perform 2 scans one after the otherParticipants will have to perform 2 scans one after the other
• Masking: None (Open Label)
• Primary Purpose: Health Services Research
• Official Title: Double Pet Project : A Comparison Between 11C-Acetate and 11C-acetoacetate Heart and
• Anticipated Study Start Date: Feb 1, 2022
• Anticipated Primary Completion Date: Jun 1, 2022
• Anticipated Study Completion Date: Dec 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Other: Observational heart and kidney metabolism Participants will have a PET scan with 11C-Acetate followed by a TEP Scan with 11C-Acetoacetate all in the same day.	Radiation: Observational heart and kidney on siemens TEP scan; Same as arm description

Outcome Measures

Primary Outcome Measures

1. Mean in left ventricule myocradial blood flow [30 minutes]

   Heart acetate metabolism measured by TEP scan

2. Mean in left ventricule myocardial blood flow [30 minutes]

   Heart acetoacetate metabolism measured by TEP scan

3. Mean in Kidney acetate uptake [30 minutes]

   Kidney acetate uptake measured by TEP scan

4. Mean in Kidney acetoacetate uptake [30 minutes]

   Kidney acetoacetate uptake measured by TEP scan.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 55 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Aged between 18 and 55

• BMI between 18,5 and 28

• Healthy

• Normal value for blood pressure

Exclusion Criteria:

• Taking drugs that could influence metabolism

• Diabetes or prediabetes

• Pregnancy or lactation

• Participation in a intensive sport program

• Being on a ketogenic diet

• Any clinical abnomally in prescreen blood sample

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Université de Sherbrooke
• Nestlé Health Science Spain

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Université de Sherbrooke
• ClinicalTrials.gov Identifier: NCT05238805
• Other Study ID Numbers: 2022-4540
• First Posted: Feb 14, 2022
• Last Update Posted: Feb 24, 2022
• Last Verified: Feb 1, 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Université de Sherbrooke: ketones; heart metabolism; kidney metabolism
• Additional relevant MeSH terms: Ketosis

Study Results

No Results Posted as of Feb 24, 2022